Hememics
1 known investors
Hememics develops FAST™, an immunoassay-based screening technology that detects multiple antibody targets in under one hour using custom user-supplied antibodies and antigens. The platform serves life sciences researchers and diagnostic laboratories as a faster and lower-cost alternative to traditional ELISA and Western blotting methods.
Investors · 1
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $185.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
- Hememics Biotech raises a $2 million seed round | Graphene-Infographene-info.com · 2023
- Hememics Biotechnologies Closes $2M Seed 2 Financingfinsmes.com · 2023
- Hememics Biotechnologies, Inc. Announces Successful Close in $2 Million Seed 2 Financing from TEDCO and Qualified Investors to Accelerate Growthprnewswire.com · 2023
- Hememics BARDA Funding for COVID-19 Rapid Test | M2D2 BlogM2D2blogs.uml.edu · 2020